Zenas BioPharma releases Phase 3 obexelimab IgG4-related disease data with open-label extension results showing durability ...
“Study builds [in TrialKit] went from anywhere from two to six weeks to one to three to four days. The work Floyd is doing on ...
WCG's Activation Intelligence saves 20+ hours per study activation. Here's what that number means for site startup budgets ...
Heart failure Phase IV studies use digital tools and remote monitoring to reduce patient dropout when perceived personal ...
Proteomic aging clocks are moving into clinical trials, but FDA surrogate endpoint standards and assay reproducibility gaps ...
FDA grants priority review to BridgeBio's oral infigratinib for pediatric achondroplasia, offering a once-daily pill ...
When scan sets split into separate rows, MCAs lose the parent schedule. Here is what that costs you and how to fix it.
Clinical Solutions hosts ENGAGE 2026 with 250+ attendees exploring clinical data management solutions for FDA compliance and ...
TRIUMPH-2's Phase 3 data on retatrutide in 1,152 T2D patients challenges every assumption sponsors hold about GLP-1 trial ...
ArkBio receives FDA clearance for AK0406, a drug-Fc conjugate designed to prevent influenza in adults during the upcoming U.S ...
FDA flagged four patient deaths in evenamide's schizophrenia trial. The question isn't the drug, it's why real-time ...
AKIR001 radiopharmaceutical shows no dose-limiting toxicities in eight patients, with imaging confirming selective tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results